Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Pergoveris Market Growth Potential: How Will Market Size Shift Through 2030?
Historical growth stemmed from a rise in the diagnosis of gonadotropin deficiencies, the proliferation of assisted reproductive technology clinics, improved success rates for IVF treatments, the introduction and accessibility of recombinant hormone technologies, and heightened awareness regarding infertility.
The anticipated growth during the forecast period stems from a heightened demand for advanced in vitro fertilization protocols, an escalating emphasis on precision hormone therapy, the proliferation of fertility tourism, the growing adoption of patient-friendly injectable formats, and increasing investments in reproductive biotechnology.
Key trends observable in the forecast period encompass a rising adoption of recombinant hormone therapies, an escalating demand for IVF and Assisted Reproductive Technology procedures, the growing use of injectable pen formulations, the expansion of precision-controlled fertility treatments, and an enhanced focus on hormone deficiency management.
Get A Free Sample Report With In-Depth Market Insights:
Pergoveris Market Development Factors: What’s Supporting Demand?
The increasing prevalence of infertility is anticipated to stimulate the growth of the pergoveris market going forward. Infertility denotes the incapacity to conceive, sustain a pregnancy, or carry it to full term. The increase in infertility is attributed to factors such as delaying parenthood, various lifestyle choices, exposure to environmental toxins, and the growing occurrence of medical conditions like polycystic ovary syndrome (PCOS) and endometriosis. Pergoveris aids infertility patients by activating ovarian function through its blend of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which encourages the maturation of eggs in women suffering from severe gonadotropin deficiency. For example, in April 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that around 17.5% of the global adult population, or approximately 1 in 6 individuals, experience infertility. Thus, the rising incidence of infertility is a significant driver for the expansion of the pergoveris market.
Pergoveris Market Segment Outlook: Which Categories Are Growing Fastest?
The pergoveris market covered in this report is segmented –
1) By Formulation: Injectable Pen, Vial Formulation
2) By Indication: Anovulation, Assisted Reproductive Technology (ART) Procedures
3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Pergoveris Market Transformation Trends: What Innovations Are Driving Change?
Leading pharmaceutical firms within the pergoveris market are concentrating their efforts on driving advancements related to regulations and patient accessibility. These include strategies like priority-review filings facilitated by the FDA Commissioner’s National Priority Voucher (CNPV) program, with the aim of shortening approval durations, broadening patient access, and making intricate fertility treatments more affordable. This particular filing mechanism enables regulatory bodies to condense the typical review timeframe from 10–12 months down to 1–2 months, thereby accelerating the introduction of novel reproductive therapies without compromising their safety or effectiveness. An example of this is the October 2025 submission of Pergoveris® by EMD Serono, which is Merck KGaA, Darmstadt, Germany’s healthcare division, under the FDA CNPV program. This specific treatment unites recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) in a 2:1 ratio, administered through a pre-filled Redi-ject® pen for easier dosing, fewer injections, and an improved overall patient experience. Pergoveris is engineered to replicate the body’s natural reproductive processes, aiding in follicular development and maturation during medically assisted reproductive cycles. Furthermore, the program is consistent with both public-private collaborations and direct-to-consumer access initiatives, ultimately enhancing affordability and broadening the range of treatment choices for women experiencing severe FSH/LH deficiency.
Pergoveris Market Leading Companies And Competitive Benchmarking
Major companies operating in the pergoveris market are Merck KGaA
View The Full Pergoveris Market Report:
Pergoveris Market Regional Analysis: Which Geography Leads On Revenue?
Europe was the largest region in the pergoveris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pergoveris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
